Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Dow
Queensland Health
Mallinckrodt
Medtronic
Chubb
Accenture
Baxter
Daiichi Sankyo

Generated: May 27, 2018

DrugPatentWatch Database Preview

Taro Pharm Company Profile

« Back to Dashboard

What is the competitive landscape for TARO PHARM, and what generic alternatives to TARO PHARM drugs are available?

TARO PHARM has thirty-nine approved drugs.

There are three US patents protecting TARO PHARM drugs. There are two tentative approvals on TARO PHARM drugs.

There are twenty-five patent family members on TARO PHARM drugs in thirteen countries and twenty-two supplementary protection certificates in nine countries.

Summary for Taro Pharm
International Patents:25
US Patents:3
Tradenames:36
Ingredients:33
NDAs:39
Patent Litigation for Taro Pharm: See patent lawsuits for Taro Pharm

Drugs and US Patents for Taro Pharm

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Taro Pharm AMIODARONE HYDROCHLORIDE amiodarone hydrochloride TABLET;ORAL 075424-002 Dec 18, 2002 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Taro Pharms North PSORCON diflorasone diacetate CREAM;TOPICAL 020205-001 Nov 20, 1992 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Taro Pharm CLORAZEPATE DIPOTASSIUM clorazepate dipotassium TABLET;ORAL 075731-001 Apr 27, 2000 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Taro Pharm AMIODARONE HYDROCHLORIDE amiodarone hydrochloride TABLET;ORAL 075424-001 Mar 30, 2001 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for TARO PHARM drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Topical Lotion 0.5% ➤ Subscribe 2011-03-16

Non-Orange Book US Patents for Taro Pharm

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,957,238 Process for preparing malathion for pharmaceutical use ➤ Try a Free Trial
8,039,657 Process for preparing malathion for pharmaceutical use ➤ Try a Free Trial
8,536,155 Process for preparing malathion for pharmaceutical use ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Taro Pharm Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0067 France ➤ Try a Free Trial PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
2013025,C1304992 Lithuania ➤ Try a Free Trial PRODUCT NAME: CLINDAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
C/GB08/005 United Kingdom ➤ Try a Free Trial SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
01C/013 Belgium ➤ Try a Free Trial PRODUCT NAME: DESLORATADINE; REGISTRTION NO/DATE: EU/1/00/160/010 20010115
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Queensland Health
Baxter
US Army
Cantor Fitzgerald
Cerilliant
Merck
Federal Trade Commission
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.